Skip to main content
Equibles
SRTA logo

SRTA · Strata Critical Medical, Inc. · Metrics

Track SRTA — free

Use SRTA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SRTA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.56 +0.30 (+5.70%) At close · Nov 6 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$491.43M
Shares
88.47M
Volume · Nov 6 1.35M Avg daily vol (3M) 944.97K

SRTA metrics

95 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.56
Market cap
$491.43M

Price action

23 metrics
Price change (1W)
+10.7%
Price change (30D)
+12.4%
Price change (3M)
-5.9%
Price change (6M)
-1.5%
Price change (YTD)
+9.4%
Price change (1Y)
+13.9%
Trailing year
Price change (5Y)
-47.9%
52-week high
$6.47
52-week low
$4.03
Change from 52-week high
-18.7%
Change from 52-week low
+30.5%
Annualized volatility
57.0%
Annualized volatility (3M)
54.1%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.0
RSI (14D)
62.5
Price vs SMA 50
+5.2%
Price vs SMA 200
+3.6%
Avg volume (3M)
942,424
Relative volume
1.8
Average dollar volume
$4.88M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
88.47M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.6×
reciprocal yield 64.5%
EV / EBITDA
132.9×
reciprocal yield 0.8%
EV / EBIT
—
P / sales
1.7×
reciprocal yield 59.7%
P / book
1.7
reciprocal yield 58.7%
FCF yield
0.2%
TTM · current market cap
Buyback yield
—
P / FCF
583.9
reciprocal yield 0.2%
P / operating cash flow
43.9
reciprocal yield 2.3%
Earnings yield
-5.3%

Historical valuation

8 metrics
P / E historical average (3Y)
10.0×
reciprocal yield 10.0%
P / E historical average (5Y)
10.0×
reciprocal yield 10.0%
EV / revenue historical average (3Y)
1.2×
reciprocal yield 81.3%
EV / revenue historical average (5Y)
1.3×
reciprocal yield 79.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-03

Profitability

9 metrics
Gross margin
21.6%
Operating margin
-6.6%
Trailing 12 months
Net margin
-8.8%
Gross profit (TTM)
$60.56M
Operating profit (TTM)
−$18.62M
Net income (TTM)
−$24.81M
Trailing 12 months
Diluted EPS (TTM)
$-0.29
FCF margin
0.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$3.22
Gross profit per diluted share (TTM)
$0.69
Operating profit per diluted share (TTM)
$-0.21
EBITDA per diluted share (TTM)
$0.04
Net income per diluted share (TTM)
$-0.29
Operating cash flow per diluted share (TTM)
$0.12
Free cash flow per diluted share (TTM)
$0.01
Capital expenditures per diluted share (TTM)
$0.11
R&D per diluted share (TTM)
$0.04
Stock compensation per diluted share (TTM)
$0.23
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+50.3%
Year over year
Net income growth YoY
-113.3%
Revenue (TTM)
$280.76M
Trailing 12 months
EPS growth YoY
-112.9%
Shares change YoY
+7.1%
Year over year · more shares
Revenue CAGR (3Y)
+10.5%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-9.0%
Return on assets
-7.5%
Debt / equity
0.0
Current ratio
2.8
EBITDA (TTM)
$3.28M
Free cash flow (TTM)
$806,000
Quick ratio
2.8
Interest coverage
—
Net debt / EBITDA
-10.7
Return on invested capital
—
Trailing 12 months
Net cash
$35.14M
Latest balance sheet
Cash & equivalents
$35.14M
Total assets
$328.88M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$10.72M
Capital expenditures (TTM)
$9.92M
R&D (TTM)
$3.31M
SG&A (TTM)
$64.08M
Stock compensation (TTM)
$20.38M
R&D / revenue
—
Stock compensation / revenue
7.3%

Ownership (13F)

9 metrics
13F filers
141
13F filer change QoQ
+15
Institutional ownership
63.7%
Conviction holders (share of 13F filers)
1.4%
Crowding (high-turnover and private-fund holders)
37.9%
Private-fund adviser ownership
37.1%
Active holders' share change QoQ
-5.7%
Holder tenure
9.4
Price vs estimated holder cost
+4.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.4%

Short interest

3 metrics
Short interest
5.1%
Latest settlement · 5.0 days to cover
Days to cover
5.0d
Short-squeeze score
87 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$29,273
Insider-sentiment score
52 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1779128 CUSIP 092667104 13F (30d) 70 filings 55 filers Visit website Investor relations